ArticleThoracic cancer2025
There Is More Than Meets the Eye With Ground Glass Nodules: Is It Too Early to Adopt Sublobar Resection as Standard of Care for Early Stage Lung Adenocarcinoma?
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sublobar resection is gaining popularity for the treatment of early stage lung adenocarcinoma, often presenting as a ground glass nodule on CT. Ground glass nodules are, however, a heterogeneous group of lesions, and they are too often equated with in situ or lepidic pattern adenocarcinoma. Many of these lesions actually harbor high grade micropapillary pattern and display spread through air spaces (STAS) on histology; features that are associated with increased recurrence following sublobar resection. Post hoc analysis of the impact of STAS in the JCOG0802 and CALGB140503 trials is currently ongoing and has yet to be published. This brief report aims to raise awareness of these pertinent issues that should be considered when approaching the management of early stage lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.